Request Trial
12 April 2017Americas

Eight drugs expected to reach blockbuster status by 2021, says report

The 2017 “Drugs to Watch” report predicts that eight new drugs will enter the market this year and each achieve $1 billion in annual sales by 2021.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
10 February 2026   Telehealth platform faces legal action from the Danish pharma giant, as well as FDA pressure over GLP-1 drugs and a drop in shares after discontinuing new product.
Americas
Novartis takes aim at Tafinlar generic in latest suit
9 February 2026   The Swiss pharma giant moves to protect patents on its billion-dollar cancer therapy following an ANDA filing by a Canadian generics manufacturer.
Americas
Semaglutide patent battle heats up with new blow for Novo in India
6 February 2026   A Delhi High Court ruling signals more bad news for the Danish pharma giant in the same week that it lost nearly $50 billion in value.


Editor's picks

Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
Americas
Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
10 February 2026

Editor's picks

Americas
Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
10 February 2026
Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026
Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026
Americas
Bayer enters COVID-19 vaccine row with three suits against major drugmakers
8 January 2026
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025
Europe
Abbott appeals ‘baffling’ decision in glucose monitoring device feud
16 December 2025

More features

New rankings recognise top US patent firms and lawyers
Norton Rose Fulbright expands pharma and biotech disputes team
UPC appeals court confirms ‘all-or-nothing’ rule for unitary patents
Honigman bags second Kirkland litigator this year for IP team
Reaction: Emotional Perception decision is ‘good for UK PLC’
UK ruling ‘future-proofs’ patentability for AI and computer tech
The curtain closes on three major drug disputes
Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’